Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 6/20 | 0.44 |
| ▸ | CDK2 | P24941 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28226632 | 0.88 | ALDH1A1 (0.45) | ALDH1A1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL28061957 | 0.86 | ALDH1A1 (0.46) | ALDH1A1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL28300921 | 0.85 | TSHR (0.53) | ALDH1A1TDP1TSHRCYP3A4ALOX15 | |
| SCHEMBL2381586 | 0.82 | TSHR (0.54) | ALDH1A1TDP1TSHRCYP3A4ALOX15 | |
| SCHEMBL30729473 | 0.82 | ALDH1A1 (0.50) | ALDH1A1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL8668862 | 0.82 | ALDH1A1 (0.50) | ALDH1A1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL8063523 | 0.81 | ALDH1A1 (0.49) | ALDH1A1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL611879 | 0.81 | ALDH1A1 (0.49) | ALDH1A1CYP1A2CYP2D6CYP2C19TDP1 | |
| SCHEMBL2598195 | 0.81 | TDP1 (0.49) | ALDH1A1TDP1TSHRCYP3A4ALOX15 | |
| SCHEMBL5314234 | 0.81 | ALDH1A1 (0.47) | ALDH1A1TDP1TSHRCDK2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163935-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090312383-A1 | Fused Heterocyclic Compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-12-17 | — | — | US | disclosed |
| EP-1874736-A4 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2008-08-20 | — | — | EP | disclosed |
| EP-1874736-A2 | FUSED HETEROCYCLIC COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006116412-A2 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-11-02 | — | — | WO | disclosed |
| EP-1349836-B1 | TETRACYCLIC DERIVATIVES AS SPLA2 INHIBITORS | LILLY CO ELI (US) | 2006-06-14 | — | — | EP | disclosed |
| US-6992100-B2 | sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 2006-01-31 | — | — | US | disclosed |
| US-6872743-B2 | sPLA2 inhibitors | ELI LILLY AND COMPANY (US) | 2005-03-29 | — | — | US | disclosed |
| US-20040092543-A1 | Novel spla2 inhibitors | BEIGHT DOUGLAS WADE (US) | 2004-05-13 | — | — | US | disclosed |
| US-20040063941-A1 | Novel spla2 inhibitors | BEIGHT DOUGLAS WADE (US) | 2004-04-01 | — | — | US | disclosed |
| EP-1349836-A2 | TETRACYCLIC DERIVATIVES AS SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-10-08 | — | — | EP | disclosed |
| EP-1345898-A2 | TERACYCLIC CARBAZOLE DERIVATES AND THEIR USE AS SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2003-09-24 | — | — | EP | disclosed |
| WO-2002050034-A2 | TETRACYCLIC CARBAZOLE DERIVATES AND THEIR USE AS SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-06-27 | — | — | WO | disclosed |
| WO-2002050029-A2 | TETRACYCLIC DERIVATIVES AS SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2002-06-27 | — | — | WO | disclosed |
| US-4036838-A | Process for the production of nitro derivatives of aromatic compounds | BAYER AKTIENGESELLSCHAFT (DT) | 1977-07-19 | — | — | US | disclosed |
| US-3954396-A | MONOAZO | CASSELLA FARBWERKE MAINKUR AKTIENGESELLSCHAFT (DT) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063941-A1 | Novel spla2 inhibitors | PLA2G12A, PLAAT2, SPINT2 | ALDH1A1 3948/4885CYP1A2 2256/4885CYP2D6 3989/4885 |
| US-20040092543-A1 | Novel spla2 inhibitors | PLA2G12A, PLAAT2, SPINT2 | ALDH1A1 3868/4885CYP1A2 2345/4885CYP2D6 4116/4885 |
| US-20090312383-A1 | Fused Heterocyclic Compounds | NPY4R, CRHR1, CNR1 | ALDH1A1 2007/4885CYP1A2 580/4885CYP2D6 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.